Hospitalizations and Deaths Among Adults With Cardiovascular Disease Who Underuse Medications Because of Cost: A Longitudinal Analysis

Context:It is well-documented that the financial burden of out-of-pocket expenditures for prescription drugs often leads people with medication-sensitive chronic illnesses to restrict their use of these medications. Less is known about the extent to which such cost-related medication underuse is associated with increases in subsequent hospitalizations and deaths. Objective:We compared the risk of hospitalizations among 5401 and of death among 6135 middle-aged and elderly adults with one or more cardiovascular diseases (diabetes, coronary artery disease, heart failure, and history of stroke) according to whether participants did or did not report restricting prescription medications because of cost. Design and Setting:A retrospective biannual cohort study across 4 cross-sectional waves of the Health and Retirement Study, a nationally representative survey of adults older than age 50. Using multivariate logistic regression to adjust for baseline differences in sociodemographic and health characteristics, we assessed subsequent hospitalizations and deaths between 1998 and 2006 for respondents who reported that they had or had not taken less medicine than prescribed because of cost. Results:Respondents with cardiovascular disease who reported underusing medications due to cost were significantly more likely to be hospitalized in the next 2 years, even after adjusting for other patient characteristics (adjusted predicted probability of 47% compared with 38%, P < 0.001). The more survey waves respondents reported cost-related medication underuse during 1998 to 2004, the higher the probability of being hospitalized in 2006 (adjusted predicted probability of 54% among respondents reporting cost-related medication underuse in all 4 survey waves compared with 42% among respondents reporting no underuse, P < 0.001). There was no independent association of cost-related medication underuse with death. Conclusions:In this nationally representative cohort, middle-aged and elderly adults with cardiovascular disease who reported cutting back on medication use because of cost were more likely to report being hospitalized over a subsequent 2-year period after they had reported medication underuse. The more extensively respondents reported cost-related underuse over time, the higher their adjusted predicted probability of subsequent hospitalization.

[1]  A. Fendrick,et al.  Impact of decreasing copayments on medication adherence within a disease management environment. , 2008, Health affairs.

[2]  K. Rost,et al.  Predictors of recall of medication regimens and recommendations for lifestyle change in elderly patients. , 1987, The Gerontologist.

[3]  M. Olfson,et al.  Medication costs, adherence, and health outcomes among Medicare beneficiaries. , 2003, Health affairs.

[4]  T. Wagner,et al.  Cost-related medication underuse: do patients with chronic illnesses tell their doctors? , 2004, Archives of internal medicine.

[5]  A. Rosen.  Grounding coverage in value: a paradigm for linking quality and costs. , 2006, Medical care.

[6]  R. Verbrugge,et al.  Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost , 2005, Medical care.

[7]  M. Solomon,et al.  Employer drug benefit plans and spending on prescription drugs. , 2002, JAMA.

[8]  Dana P Goldman,et al.  Prescription drug cost sharing: associations with medication and medical utilization and spending and health. , 2007, JAMA.

[9]  F. Lichtenberg,et al.  The impact of Medicare Part D on prescription drug use by the elderly. , 2007, Health affairs.

[10]  E. Cox,et al.  Medicare Beneficiaries’ Management of Capped Prescription Benefits , 2001, Medical care.

[11]  Dana P Goldman,et al.  Varying pharmacy benefits with clinical status: the case of cholesterol-lowering therapy. , 2006, The American journal of managed care.

[12]  K. Langa,et al.  The Health Effects of Restricting Prescription Medication Use Because of Cost , 2004, Medical care.

[13]  B. Martin,et al.  The impact of implementing a more restrictive prescription limit on Medicaid recipients. Effects on cost, therapy, and out-of-pocket expenditures. , 1996, Medical care.

[14]  B. Stricker,et al.  Agreement between the pharmacy medication history and patient interview for cardiovascular drugs: the Rotterdam elderly study. , 1998, British journal of clinical pharmacology.

[15]  William H Shrank,et al.  Cost-Effectiveness of Providing Full Drug Coverage to Increase Medication Adherence in Post–Myocardial Infarction Medicare Beneficiaries , 2008, Circulation.

[16]  A Norrish,et al.  Validity of self-reported hospital admission in a prospective study. , 1994, American journal of epidemiology.

[17]  Christopher T. Erb,et al.  Prescription noncompliance due to cost among adults with disabilities in the United States. , 2002, American journal of public health.

[18]  S B Soumerai,et al.  Effects of Medicaid drug-payment limits on admission to hospitals and nursing homes. , 1991, The New England journal of medicine.

[19]  S B Soumerai,et al.  Payment restrictions for prescription drugs under Medicaid. Effects on therapy, cost, and equity. , 1987, The New England journal of medicine.

[20]  A. Fendrick,et al.  A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. , 2001, The American journal of managed care.

[21]  T. Wagner,et al.  Cost-related medication underuse among chronically ill adults: the treatments people forgo, how often, and who is at risk. , 2004, American journal of public health.

[22]  C. Hanson,et al.  Coping with the Cost of Prescription Drugs , 1996, Journal of health care for the poor and underserved.

[23]  R. Kington,et al.  Insurance coverage for prescription drugs: effects on use and expenditures in the Medicare population. , 1999, Medical care.

[24]  J A Hanley,et al.  Adverse events associated with prescription drug cost-sharing among poor and elderly persons. , 2001, JAMA.

[25]  M. Weinstein,et al.  Cost-Effectiveness of Full Medicare Coverage of Angiotensin-Converting Enzyme Inhibitors for Beneficiaries with Diabetes , 2005, Annals of Internal Medicine.

[26]  D. Steinwachs.  Pharmacy benefit plans and prescription drug spending. , 2002, JAMA.

[27]  S. Soumerai,et al.  Inadequate Prescription-Drug Coverage for Medicare Enrollees — A Call to Action , 2017 .

[28]  M. Adams,et al.  Patients as Reliable Reporters of Medical Care Process: Recall of Ambulatory Encounter Events , 1992, Medical care.

[29]  F. Lichtenberg.  Do (more and better) drugs keep people out of hospitals? , 1996, The American economic review.

[30]  B. Stuart,et al.  Ability to pay and the decision to medicate. , 1998, Medical care.

[31]  R. Schulz,et al.  Payment Restrictions for Prescription Drugs under Medicaid , 1992, PharmacoEconomics.

[32]  Lola Butcher,et al.  Value-based insurance design. , 2009, Biotechnology healthcare.

[33]  Todd H Wagner,et al.  Problems paying out-of-pocket medication costs among older adults with diabetes. , 2004, Diabetes care.

[34]  D A Savitz,et al.  Recall accuracy for prescription medications: self-report compared with database information. , 1995, American journal of epidemiology.

[35]  D. Meltzer,et al.  The Effect of the Medicare Part D Prescription Benefit on Drug Utilization and Expenditures , 2008, Annals of Internal Medicine.

[36]  Rodney A Hayward,et al.  Mechanisms for racial and ethnic disparities in glycemic control in middle-aged and older Americans in the health and retirement study. , 2007, Archives of internal medicine.

[37]  S. Soumerai,et al.  Effects of Limiting Medicaid Drug-Reimbursement Benefits on the Use of Psychotropic Agents and Acute Mental Health Services by Patients with Schizophrenia , 1994 .

[38]  D. Baker,et al.  Loss of Health Insurance and the Risk for a Decline in Self-Reported Health and Physical Functioning , 2002, Medical care.

[39]  J. Feinglass,et al.  Health Insurance Coverage and the Risk of Decline in Overall Health and Death Among the Near Elderly, 1992–2002 , 2006, Medical care.

[40]  A. Rosen,et al.  Linking Cost Sharing to Value: An Unrivaled Yet Unrealized Public Health Opportunity , 2007, Annals of Internal Medicine.

[41]  I. Wilson,et al.  Prescription drug coverage and seniors: findings from a 2003 national survey. , 2005, Health affairs.

[42]  F. Lichtenberg,et al.  Are the benefits of newer drugs worth their cost? Evidence from the 1996 MEPS. , 2001, Health affairs.

[43]  B. Soldo,et al.  Asset and Health Dynamics Among the Oldest Old: an overview of the AHEAD Study. , 1997, The journals of gerontology. Series B, Psychological sciences and social sciences.